Biodexa Pharmaceuticals Plc
BDRX · Pharmaceutical Preparations
Latest available SEC filing: 20-F ·
Latest disclosures
-
Latest financial period: Q4 2025
Financial facts · Filed
-
Form 20-F
SEC filing · Filed
-
Parker Stephen Barry: Form 3
Insider disclosure · Filed · Report period 18 Mar 2026
-
Form 3
SEC filing · Filed
-
Form 3
SEC filing · Filed
-
Form 3
SEC filing · Filed
-
Form 3
SEC filing · Filed
-
Form 3
SEC filing · Filed
Institutional holders by security
Choose a share class to see reported 13F positions and quarterly changes. Different securities have separate holder histories.
- BDRX · 59564R872 - American Depositary Shares, each representing four hundred ordinary shares
- BDRX · 59564R880 - American Depositary Shares, each representing four hundred ordinary shares
- BDRX · 59564R708 - SPON ADS NEW
- BDRX · 59564R807 - Ordinary Shares, nominal value 0.00005 GBP per share
- BDRX · 59564R609 - SPON ADS NEW
Company details and SEC sources
CIK 0001643918 · SEC filing index. Filing dates describe disclosures, not live market data.
- Listed symbols
- BDRX on Nasdaq
- SEC industry group
- Pharmaceutical Preparations (Office of Life Sciences)
- Business address
- 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ
- Incorporated in
- United Kingdom
- Fiscal year end
- 31 December
- Former names on EDGAR
- Midatech Pharma Plc (to 27 Mar 2023)
At a glance
Names, identifiers, and filing context for this profile.
2 identity fields